Burçin Çakan Demirel

13PUBLICATIONS
62CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Clinical midwiferyNutrigenomics and personalised nutrition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 15, 2026
Association of Pretreatment Immune-Inflammatory Biomarkers with Pathological Tumor Regression Following Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

|May 04, 2026
Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

|May 04, 2026
A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

|Mar 28, 2026
Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Maral Martin Mildanoglu, Mehmet Haluk Yucel, Ebru Engin Delipoyraz

|Mar 28, 2026
Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR.

Ayberk Bayramgil, Mehmet Haluk Yücel, Ezgi Turkoglu

|Mar 14, 2026
Association of Post-Neoadjuvant Chemotherapy MRI and 18F-FDG PET/CT Findings with Tumor Response and Prognosis in Breast Cancer.

Burçin Çakan Demirel, Semra Taş, Ayberk Bayramgil

Pageof 3

Frequent Collaborators

5 joint publications

Ahmet Bilici

4 joint publications

Mehmet Haluk Yücel

4 joint publications

Melek Özdemir

3 joint publications

Atike Gökçen Demiray